摘要:
Diseases which can be ameliorated by delivery of NO to tissues affected by the disease can be treated by administration of nitrosyl-heme-containing donors of NO, including nitrosylhemoglobin. Nitrosylhemoglobin can be made by the reaction of NO with hemoglobin under certain conditions in which the NO:hemoglobin ratio is critical, and is converted to SNO-Hb under physiological conditions.
摘要:
Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
摘要:
Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.
摘要:
NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a cooperative manner, nitrosylates hemoglobin thiols, or reacts with liberated superoxide in solution. The distribution of minor forms of hemoglobin can be tested and the results can be used to predict whether a composition of hemoglobin will scavenge, load, eliminate, or donate NO. Hemoglobin thus serves to regulate the chemistry of NO. SNO-hemoglobin transfers NO equivalents to the red blood cell anion transport protein AE1, which serves to export NO from red blood cells. Regulation of AE1 function is the basis for methods of therapy to affect levels of NO or its biological equivalent.
摘要:
Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.
摘要翻译:与低氧血症和/或平滑肌收缩和/或炎症相关的肺部疾病的治疗包括将作为不形成NO 2的NO组的气体化合物施用于肺部, / SUB>在体温存在氧或活性氧的情况下。 治疗心脏和血液疾病,例如心绞痛,心肌梗塞,心力衰竭,高血压,镰状细胞病和凝血障碍,包括作为气体施用于肺部,与血红蛋白中的半胱氨酸反应和/或溶解于血液中的化合物和 具有在所述化合物中结合的NO基团,使得其在体温存在氧或活性氧的情况下不形成NO 2 / NO x 2 x。 在每种情况下施用的化合物的实例是亚硝酸乙酯。
摘要:
Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.
摘要翻译:与低氧血症和/或平滑肌收缩相关的肺部疾病的治疗包括在体温下在氧气或活性氧存在的情况下向肺中施用具有NO基团的化合物作为气体,所述NO组不形成NO 2 / NO x。 治疗心脏和血液疾病,例如心绞痛,心肌梗死,心力衰竭,高血压,镰状细胞病和凝血障碍,包括作为气体给予肺,与血红蛋白中的半胱氨酸反应和/或溶解于血液中的化合物和 具有在所述化合物中结合的NO基团,使得其在体温存在氧或活性氧的情况下不形成NO 2 / NO x。 在每种情况下施用的化合物的实例是亚硝酸乙酯。